3//SEC Filing
Decheng Capital Global Life Sciences Fund IV, L.P. 3
Accession 0001104659-21-024391
CIK 0001746466other
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 5:22 PM ET
Size
9.5 KB
Accession
0001104659-21-024391
Insider Transaction Report
Form 3
Holdings
- 3,285,710(indirect: See Footnote)
Common Stock
- (indirect: See Footnote)
Warrant (right to buy)
Exercise: $14.00From: 2021-02-05Exp: 2026-02-05→ Common Stock (985,713 underlying)
Cui Xiangmin
10% Owner
Holdings
- 3,285,710(indirect: See Footnote)
Common Stock
- (indirect: See Footnote)
Warrant (right to buy)
Exercise: $14.00From: 2021-02-05Exp: 2026-02-05→ Common Stock (985,713 underlying)
Holdings
- 3,285,710(indirect: See Footnote)
Common Stock
- (indirect: See Footnote)
Warrant (right to buy)
Exercise: $14.00From: 2021-02-05Exp: 2026-02-05→ Common Stock (985,713 underlying)
Footnotes (2)
- [F1]The reportable securities are included within 3,285,710 units representing (i) 3,285,710 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) warrants to purchase an additional 985,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock).
- [F2]The reportable securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (the "Fund"). Decheng Capital Management IV (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
Equillium, Inc.
CIK 0001746466
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001834150
Filing Metadata
- Form type
- 3
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 5:22 PM ET
- Size
- 9.5 KB